Reuters: Regulatory News: UPDATE 1-US FDA staff shoots down Pfizer rare disease drug

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-US FDA staff shoots down Pfizer rare disease drug May 22nd 2012, 13:52 Tue May 22, 2012 9:52am EDT * FDA staff recommend rejection because data not convincing * Outside advisers to FDA to vote on drug on Thursday WASHINGTON May 22 (Reuters) - U.S. drug reviewers on Tuesday recommended rejecting a Pfizer Inc drug because the data did not prove it worked well in treating a rare neurodegenerative disease. The U.S. Food and Drug Administration staff reviewed the pill, tafamidis, ahead of an advisory panel of outside experts, which will vote on whether to recommend it for approval on Thursday. The FDA will make a final decision later, taking into account the panel's recommendation. Tafamidis, which is already approved in Europe under the name Vyndaqel, is meant to treat familial amyloid polyneuropathy, a fatal condition that affects as many as 10,000 people worldwide, including about 2,500 Americans. Most people with the genetic mutation that is thought to cause the disease live in Portugal, Sweden or Japan. Once symptoms begin, most people die in 11 years, the FDA said. The only current treatment for the disease is a liver transplant, which keeps 80 percent of patients alive after five years. Two FDA reviewers said during a clinical trial that tafamidis was most successful in treating people in Portugal, but the data did not prove it helped those with the disease in other locations. People taking tafamidis during clinical trials also appeared to have a milder disease than those taking a placebo, which could skew the results, they said. Link this Share this Digg this Email Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions